Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$58.39 - $296.54 $52,551 - $266,886
900 New
900 $261,000
Q2 2022

Aug 15, 2022

SELL
$58.04 - $100.2 $173,075 - $298,796
-2,982 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$55.89 - $101.89 $122,958 - $224,158
-2,200 Reduced 42.45%
2,982 $293,000
Q4 2021

Feb 14, 2022

SELL
$72.34 - $95.09 $2.2 Million - $2.9 Million
-30,458 Reduced 85.46%
5,182 $439,000
Q3 2021

Nov 15, 2021

SELL
$78.35 - $105.02 $3.86 Million - $5.18 Million
-49,300 Reduced 58.04%
35,640 $2.84 Million
Q2 2021

Aug 16, 2021

SELL
$97.2 - $137.59 $3 Million - $4.25 Million
-30,900 Reduced 26.67%
84,940 $8.27 Million
Q1 2021

May 17, 2021

BUY
$108.54 - $125.2 $8.28 Million - $9.55 Million
76,300 Added 192.97%
115,840 $13.6 Million
Q4 2020

Feb 16, 2021

BUY
$110.06 - $133.7 $2.31 Million - $2.81 Million
21,000 Added 113.27%
39,540 $4.4 Million
Q3 2020

Nov 16, 2020

BUY
$99.78 - $124.21 $632,804 - $787,739
6,342 Added 51.99%
18,540 $2.2 Million
Q2 2020

Aug 14, 2020

BUY
$60.13 - $125.71 $733,465 - $1.53 Million
12,198 New
12,198 $1.38 Million
Q1 2019

May 15, 2019

SELL
$103.48 - $143.84 $2.04 Million - $2.83 Million
-19,698 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$94.77 - $215.54 $1.12 Million - $2.54 Million
11,789 Added 149.06%
19,698 $2.22 Million
Q3 2018

Nov 14, 2018

BUY
$207.3 - $300.31 $145,110 - $210,217
700 Added 9.71%
7,909 $1.69 Million
Q2 2018

Aug 14, 2018

BUY
$101.55 - $313.9 $40,620 - $125,559
400 Added 5.87%
7,209 $2.02 Million
Q1 2018

May 15, 2018

BUY
$93.35 - $149.04 $635,620 - $1.01 Million
6,809 New
6,809 $795,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.76B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.